Psyence Biomedical (PBM) Competitors $4.96 -0.15 (-2.94%) Closing price 06/27/2025 03:54 PM EasternExtended Trading$4.88 -0.08 (-1.61%) As of 06/27/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBM vs. CTXR, NKGN, PHXM, CSCI, BCDA, PHIO, EQ, AIMD, SNSE, and GLYCShould you be buying Psyence Biomedical stock or one of its competitors? The main competitors of Psyence Biomedical include Citius Pharmaceuticals (CTXR), NKGen Biotech (NKGN), PHAXIAM Therapeutics (PHXM), COSCIENS Biopharma (CSCI), BioCardia (BCDA), Phio Pharmaceuticals (PHIO), Equillium (EQ), Ainos (AIMD), Sensei Biotherapeutics (SNSE), and GlycoMimetics (GLYC). These companies are all part of the "pharmaceutical products" industry. Psyence Biomedical vs. Its Competitors Citius Pharmaceuticals NKGen Biotech PHAXIAM Therapeutics COSCIENS Biopharma BioCardia Phio Pharmaceuticals Equillium Ainos Sensei Biotherapeutics GlycoMimetics Citius Pharmaceuticals (NASDAQ:CTXR) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Does the media prefer CTXR or PBM? In the previous week, Citius Pharmaceuticals and Citius Pharmaceuticals both had 2 articles in the media. Citius Pharmaceuticals' average media sentiment score of 0.93 equaled Psyence Biomedical'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Psyence Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, CTXR or PBM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius PharmaceuticalsN/AN/A-$39.14MN/AN/APsyence BiomedicalN/AN/A-$51.16MN/AN/A Is CTXR or PBM more profitable? Psyence Biomedical's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Citius PharmaceuticalsN/A -58.63% -37.67% Psyence Biomedical N/A N/A N/A Do institutionals & insiders believe in CTXR or PBM? 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 10.7% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, CTXR or PBM? Citius Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Do analysts prefer CTXR or PBM? Citius Pharmaceuticals presently has a consensus target price of $54.50, indicating a potential upside of 3,462.09%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Psyence Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80Psyence Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCitius Pharmaceuticals beats Psyence Biomedical on 7 of the 10 factors compared between the two stocks. Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBM vs. The Competition Export to ExcelMetricPsyence BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.91M$2.84B$5.48B$8.87BDividend YieldN/A2.70%5.35%4.15%P/E RatioN/A21.1626.2119.66Price / SalesN/A282.55386.95105.10Price / CashN/A43.1436.4056.81Price / Book-0.017.207.905.44Net Income-$51.16M-$55.15M$3.16B$249.37M7 Day Performance4.20%0.76%3.08%3.98%1 Month Performance9.98%6.31%6.02%5.29%1 Year Performance-97.23%-0.21%32.07%17.08% Psyence Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBMPsyence BiomedicalN/A$4.96-2.9%N/A-97.5%$2.91MN/A0.00N/AGap DownCTXRCitius Pharmaceuticals2.7314 of 5 stars$1.29+25.2%$54.50+4,124.8%-90.4%$10.95MN/A0.0020High Trading VolumeNKGNNKGen Biotech0.379 of 5 stars$0.24+7.9%N/A-80.6%$10.79M$80K-0.05N/APHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049News CoverageCSCICOSCIENS BiopharmaN/A$3.39+0.9%N/AN/A$10.57M$9.59M-0.5820News CoveragePositive NewsGap UpBCDABioCardia3.7759 of 5 stars$2.18+7.9%$25.00+1,046.8%-28.1%$10.46M$60K-0.9440Positive NewsPHIOPhio Pharmaceuticals2.8371 of 5 stars$2.21+1.4%$14.00+533.5%-64.5%$10.46MN/A-0.2010News CoverageAnalyst ForecastEQEquillium2.394 of 5 stars$0.36+22.6%$3.00+743.9%-53.6%$10.36M$41.10M-0.9140News CoverageGap DownAIMDAinos0.9116 of 5 stars$0.50+0.3%N/A-40.9%$10.31M$20K-0.3940News CoverageHigh Trading VolumeSNSESensei Biotherapeutics4.8182 of 5 stars$8.47+5.1%$90.00+962.6%-35.3%$10.16MN/A-0.3740Positive NewsGap DownGLYCGlycoMimetics1.819 of 5 stars$0.16-6.6%N/A-99.5%$10.00M$10K-0.3450High Trading Volume Related Companies and Tools Related Companies Citius Pharmaceuticals Alternatives NKGen Biotech Alternatives PHAXIAM Therapeutics Alternatives COSCIENS Biopharma Alternatives BioCardia Alternatives Phio Pharmaceuticals Alternatives Equillium Alternatives Ainos Alternatives Sensei Biotherapeutics Alternatives GlycoMimetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBM) was last updated on 6/28/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Shocking Link Between A.I. and Your MoneyThe AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
